Latest Sulfonylurea Stories

INVOKANA(TM) is the first in a new class of type 2 diabetes medications available in the United States RARITAN, N.J., March 29, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA(TM) (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA(TM) is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It...

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes) has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to a sulfonylurea in a long-term cardiovascular (CV) outcome study....

RARITAN, N.J., Sept. 25, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) will present new Phase 3 data results evaluating canagliflozin, an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, in adult patients with type 2 diabetes at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD), from October 1-5, 2012 in Berlin, Germany. "The data we will present at EASD are the latest results from our...

A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs – which account for up to 20 percent of the drugs prescribed to diabetics in the United States -- are two to three times more likely to develop bladder cancer than those who...

RIDGEFIELD, Conn. and INDIANAPOLIS, July 25, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the receipt of Marketing Authorization from the European Commission for Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.(1 ) The...

RIDGEFIELD, Conn., and INDIANAPOLIS, June 5, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American Diabetes Association (ADA) Scientific Sessions® in Philadelphia, June...

RARITAN, N.J., June 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that data from five Phase 3 clinical studies evaluating the safety and efficacy of canagliflozin, an investigational sodium glucose co-transporter 2 (SLGT2) inhibitor, will be presented at the American Diabetes Association (ADA) 72nd Annual Scientific Sessions, being held June 8-12, in Philadelphia, PA. Canagliflozin is an investigational SGLT2 inhibitor for the treatment...

RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and...

Reports new study in Parkinsonism and related disorders A major 12-year study based on a Taiwanese population cohort has demonstrated that not only does diabetes increase the risk of developing Parkinson's disease more than 2-fold, the use of sulfonylureas, commonly used as treatment for diabetes, increases the risk further by about 57%. This study also found that by including metformin in the therapy, no increased risk in developing Parkinson's disease was recorded. Metformin, found in...

RIDGEFIELD, Conn. and INDIANAPOLIS, March 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S. JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines - the...